Poly (ADP-ribose) Polymerase Inhibitors in Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2023 Dec 23

PMID 38138301

Authors

Zheng Chao

Zefeng Wang

Le Li

Yi Jiang

Yunxing Tang

Yanan Wang

Xiaodong Hao

Chunyu Zhang

Xiangdong Guo

Weimin Yu

Fan Cheng

Zhihua Wang

Affiliations

Soon will be listed here.

Abstract

: Several recent randomized controlled trials (RCTs) have reported on the survival benefits of poly (ADP-ribose) polymerase inhibitors (PARPi) compared to standard-of-care (SOC) treatment (enzalutamide, abiraterone, or docetaxel) in patients with metastatic castration-resistant prostate cancer (mCRPC). However, there is a limited integrated analysis of high-quality evidence comparing the efficacy and safety of PARPi and SOC treatments in this context. : This study aims to comprehensively analyze the survival benefits and adverse events associated with PARPi and SOC treatments through a head-to-head meta-analysis in mCRPC. : A systematic review search was conducted in PubMed, Embase, Clinical trials, and the Central Cochrane Registry in July 2023. RCTs were assessed following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. The systematic review was prospectively registered on PROSPERO (CRD42023441034). : A total of 8 studies, encompassing 2341 cases in the PARPi treatment arm and 1810 cases in the controlled arm, were included in the qualitative synthesis. The hazard ratio (HR) for radiographic progression-free survival (rPFS) and overall survival (OS) were 0.74 (95% CI, 0.61-0.90) and 0.89 (95% CI, 0.80-0.99), respectively, in the intention-to-treatment patients. For subgroup analysis, HRs for rPFS and OS in the BRCA-mutated subgroup were 0.39 (95% CI, 0.28-0.55) and 0.62 (95% CI, 0.38-0.99), while in the HRR-mutated subgroup, HR for rPFS was 0.57 (95% CI, 0.48-0.69) and for OS was 0.77 (95% CI, 0.64-0.93). The odds ratio (OR) for all grades of adverse events (AEs) and AEs with severity of at least grade 3 were 3.86 (95% CI, 2.53-5.90) and 2.30 (95% CI, 1.63-3.26), respectively. : PARP inhibitors demonstrate greater effectiveness than SOC treatments in HRR/BRCA-positive patients with mCRPC. Further research is required to explore ways to reduce adverse event rates and investigate the efficacy of HRR/BRCA-negative patients.

References

Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S . Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020; 383(24):2345-2357. DOI: 10.1056/NEJMoa2022485. View

Sciarra A, Frisenda M, Bevilacqua G, Gentilucci A, Cattarino S, Mariotti G . How the Analysis of the Pathogenetic Variants of DDR Genes Will Change the Management of Prostate Cancer Patients. Int J Mol Sci. 2023; 24(1). PMC: 9821239. DOI: 10.3390/ijms24010674. View

Pernigoni N, Guo C, Gallagher L, Yuan W, Colucci M, Troiani M . The potential role of the microbiota in prostate cancer pathogenesis and treatment. Nat Rev Urol. 2023; 20(12):706-718. DOI: 10.1038/s41585-023-00795-2. View

Thiery-Vuillemin A, de Bono J, Hussain M, Roubaud G, Procopio G, Shore N . Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an.... Lancet Oncol. 2022; 23(3):393-405. DOI: 10.1016/S1470-2045(22)00017-1. View

Saad F, Thiery-Vuillemin A, Wiechno P, Alekseev B, Sala N, Jones R . Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2022; 23(10):1297-1307. DOI: 10.1016/S1470-2045(22)00498-3. View

Cheng H, Sokolova A, Schaeffer E, Small E, Higano C . Germline and Somatic Mutations in Prostate Cancer for the Clinician. J Natl Compr Canc Netw. 2019; 17(5):515-521. DOI: 10.6004/jnccn.2019.7307. View

Gonzalez-Martin A, Pothuri B, Vergote I, Christensen R, Graybill W, Mirza M . Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019; 381(25):2391-2402. DOI: 10.1056/NEJMoa1910962. View

Hussain M, Daignault-Newton S, Twardowski P, Albany C, Stein M, Kunju L . Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2017; 36(10):991-999. PMC: 6075827. DOI: 10.1200/JCO.2017.75.7310. View

Asim M, Tarish F, Zecchini H, Sanjiv K, Gelali E, Massie C . Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017; 8(1):374. PMC: 5575038. DOI: 10.1038/s41467-017-00393-y. View

10.

Tsujino T, Takai T, Hinohara K, Gui F, Tsutsumi T, Bai X . CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nat Commun. 2023; 14(1):252. PMC: 9845315. DOI: 10.1038/s41467-023-35880-y. View

11.

Li L, Karanika S, Yang G, Wang J, Park S, Broom B . Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017; 10(480). PMC: 5855082. DOI: 10.1126/scisignal.aam7479. View

12.

Zhang Z, Diao L, Zhang C, Wang F, Guan X, Yao X . Use of PARP inhibitors in prostate cancer: from specific to broader application. Front Endocrinol (Lausanne). 2023; 14:1164067. PMC: 10162014. DOI: 10.3389/fendo.2023.1164067. View

13.

Andronikou C, Rottenberg S . Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance. Trends Mol Med. 2021; 27(7):630-642. DOI: 10.1016/j.molmed.2021.04.010. View

14.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

15.

Hankey W, Chen Z, Wang Q . Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors. Cancer Res. 2020; 80(12):2427-2436. PMC: 7299826. DOI: 10.1158/0008-5472.CAN-19-3447. View

16.

Gorchakov A, Kulemzin S, Kochneva G, Taranin A . Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer. Eur Urol. 2019; 77(3):299-308. DOI: 10.1016/j.eururo.2019.08.014. View

17.

Niazi M, Jahangir A, Sahra S, Sattar S, Asti D, Bershadskiy A . Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials. Oncology (Williston Park). 2022; 35(11):708-715. DOI: 10.46883/ONC.2021.3511.0708. View

18.

Loibl S, OShaughnessy J, Untch M, Sikov W, Rugo H, McKee M . Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018; 19(4):497-509. DOI: 10.1016/S1470-2045(18)30111-6. View

19.

Chang A, Autio K, Roach 3rd M, Scher H . High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014; 11(6):308-23. PMC: 4508854. DOI: 10.1038/nrclinonc.2014.68. View

20.

Liu S, Tu H, Wei X, Yan H, Dong X, Cui J . First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial. Nat Med. 2023; 29(8):2079-2086. DOI: 10.1038/s41591-023-02461-x. View